Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-62
Last updated

Report documents

  1. Extract of dossier assessment

    Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 287 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 287 kB, EN, not accessible)

  2. Dossier assessment

    Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 501 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 501 kB, DE, not accessible)

Dossier assessment

Indication:

Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or demonstrated by magnetic resonance imaging

Result of dossier assessment:
  • Patients who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs: added benefit not proven
  • Patients who have responded inadequately or are intolerant to prior therapy with biological antirheumatic drugs: added benefit not proven

Project details

Project no.
A23-62
Commission
Commission awarded on 03.07.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Muscles, bones and joints
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-61
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-60
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-110
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V

    Project no.
    A24-64
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page